Alexion claims Noerr-Pennington immunity in EmblemHealth US antitrust case over Soliris
Alexion Pharmaceuticals told a US judge that First Amendment petitioning protections immunize it from antitrust claims brought by insurance health plan EmblemHealth. Emblem has conceded patent litigation over Alexion’s drug Soliris...To view the full article, register now.
Already a subscriber? Click here to view full article